[1] Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer[J].Curr Treat Options Oncol,2012, 13(1):35-46.
[2] Costa Bandeira AK, Azevedo EH, Vartanian JG,et al. Quality of life related to swallowing after tongue cancer treatment[J].Dysphagia,2008, 23(2):183-192.
[3] Siegel R L , Miller K D , Jemal A . Cancer statistics, 2015 [J].CA Cancer J Clin,2010, 60(5):277-300.
[4] Franceschi D, Gupta R, Spiro RH, et al. Improved survival in the treatment of squamous carcinoma of the oral tongue[J].Am J Surg,1993, 166(4):360-365.
[5] Sutandyo N, Ramli R, Sari L, et al. Profile and survival of tongue cancer patients in "Dharmais" Cancer Hospital, Jakarta[J].Asian Pac J Cancer Prev,2014, 15(5):1971-1975.
[6] Huang SF, Tungchieh CJ, Liao CT, et al. The role of elective neck dissection in early stage buccal cancer [J].Laryngoscope,2015, 125(1):128-133.
[7] Neville BW, Day TA. Oral cancer and precancerous lesions[J].CA Cancer J Clin,2002,52(4): 195-215.
[8] Ahmedin J, Rebecca S, Elizabeth W, et al. Cancer Statistics, 2006[J].Ca A Cancer J Clin,2006, 56(2):106-130.
[9] 张良. 晚期舌癌患者扩大根治术的疗效分析[J].临床医药文献电子杂志, 2018,5(55):9.
[10] 孙小雅,严汉兴,贺莎,等.舌癌多种治疗方式的临床疗效比较[J].中南医学科学杂志,2018,46(1):16-19.
[11] 何升腾, 焦晓辉, 刘欧胜,等. 1171例舌癌的治疗与预后分析[J].重庆医学, 2014,43(6):671-673.
[12] 王佳峰, 张诠, 魏茂文,等. 143例舌体鳞状细胞癌年轻患者的预后因素[J].实用癌症杂志, 2009, 24(2):175-179.
[13] 潘懿范, 马玉波, 远奇. 90例舌癌术后患者18F-FDG符合线路显像研究及预后分析[J].标记免疫分析与临床, 2014, 21(4):419-423.
[14] Karadeniz A, Saynak M, Kadehci Z, et al. The results of combined treatment (surgery and postoperative radiotherapy) for tongue cancer and prognostic factors [J].Kulak Burun Bogaz Ihtis Derg,2007,17(7):1-6.
[15] 王艳红,陈艳峰,郭朱明,等.早期舌鳞癌复发原因及预后因素的分析[J].癌症,2009,28(5):524-527.
[16] Grandi C , Alloisio M , Moglia D , et al. Prognostic significance of lymphatic spread in head and neck carcinomas: Therapeutic implications[J].Head Neck Sur,2010, 8(2):67-73.
[17] 曹丽珍, 林国础. 267例舌癌术后相关因素分析[J].口腔颌面外科杂志, 2000, 10(2):109-112.
[18] Chen W , Kang KL , Alshaikh A , et al. Grainyhead-like 2 (GRHL2) knockout abolishes oral cancer development through reciprocal regulation of the MAP kinase and TGF-β signaling pathways[J].Oncogenesis,2018, 7(5):38.
[19] Tao Y, Sturqis EM, Huang Z, et al. TGFβ1 genetic variants predict clinical outcomes of hpv-positive oropharyngeal cancer patients after definitive radiotherapy[J].Clin Cancer Res,2018,24(9):2225-2233.
[20] Lu S L , Reh D , Li AG , et al. Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation[J].Cancer Res,2004, 64(13):4405-4410.
[21] Guo M, Mu Y, Yu D, et al. Comparison of the expression of TGF-β1, E-cadherin, N-cadherin, TP53, RB1CC1 and HIF-1α in oral squamous cell carcinoma and lymph node metastases of humans and mice [J].Oncol Lett,2018, 15(2):1639-1645.
[22] Liu TJ , Guo JL , Wang HK , et al. Semaphorin-7A contributes to growth, migration and invasion of oral tongue squamous cell carcinoma through TGF-β-mediated EMT signaling pathway[J].Eur Rev Med Pharmacol Sci,2018,22:1035-1043.
[23] Nguyen PT, Kudo Y, Yoshida M, et al, Ogawa I and Takata T: N-cadherin expression is correlated with metastasis of spindle cell carcinoma of head and neck region[J].J Oral Pathol Med,2011 ,40(1): 77-82.
[24] Davidson B, Gotlieb WH, Ben-Baruch G,et al.E-cadherin complex protein expression and survival in ovarian carcinoma[J].Gynecol Oncol,2000, 79: 362-371.
[25] Kidani K, Osaki M, Tamura T, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas[J].Oral Oncol,2009, 45(1):39-46.。
[26] Wang C, Liu X, Chen Z, et al. Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma[J].Mol Carcinog,2013, 52(3):229-236.
[27] Kakuya T, Mori T, Yoshimoto S, et al. Prognostic significance of gene amplification of ACTN4, in stage I and II oral tongue cancer[J].Int J Oral Maxillofac Surg,2017, 46(8):968-976.
[28] Yun W , Xiaojie Z , Zhi W , et al. LncRNA-p23154 promotes the invasion-metastasis potential of oral squamous cell carcinoma by regulating Glut1-mediated glycolysis[J].Cancer Lett,2018 ,434:172-183.
[29] Delilbasi CB, Okura M, Iida S, et al. Investigation of CXCR4 in squamous cell carcinoma of the tongue[J].Oral Oncol,2004, 40(2): 154-157.
[30] 农晓琳, 徐铭竹,李 昊,等. CXCR4 CD44 CD133表达在舌鳞状细胞癌患者生存分析中的价值[J].中国肿瘤临床, 2013,40(14):832-837.
[31] Chen F , Liu F , Yan L , et al. A functional haplotype of NFKB1 influence susceptibility to oral cancer: A population-based and in vitro study[J].Cancer Med,2017, 7(5):2211-2218.
[32] Welters MJP. Intratumoral HPV16-specific T cells constitute a Type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer[J].Clin Cancer Res,2018 ,24(3):634-647.
[33] Torbj rn R, Nathalie G, Tina D. Human papillomavirus and tonsillar and base of tongue cancer[J].Viruses,2015, 7(3):1332-1343.
[34] Licitra L. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma[J].J Clin Oncol,2006, 24(36):5630.
[35] Appah EO, Ballard BR, Izban MG, et al. A rapidly growing human papillomavirus-positive oral tongue squamous cell carcinoma in a 21-year old female: A case report.[J].Oncol Lett,2018, 15(5):7702-7706.
[36] Almahmoudi R, Salem A, Sievil inen M, et al. Extracellular interleukinF has a protective effect in oral tongue squamous cell carcinoma[J].Head Neck,2018, 40(10):2155-2165. |
2020, Vol. 37 
